ADRM1 and neoplasm: Further studies are warranted to address the involvement of RPN13 in cisplatin resistance, potential for greater activity of these candidate RPN13 inhibitors against tumor with compromised DNA damage responses, and the underlying mechanism of their synergy with cisplatin.